Generic User Fees: FDA Goes On Backlog Offensive
This article was originally published in The Pink Sheet Daily
Executive Summary
Officials remind industry what the formal GDUFA backlog entails and says agency is exceeding expectations for review.
You may also be interested in...
Assessment Times Improve Under GDUFA
Averages likely will increase as more of the cohort is approved, however.
Generic Drug Assessment Times Show Improvement In GDUFA Performance Report
Averages likely will increase as more of the cohort is approved, however.
Expanded Access: Reducing The Contract Delay
While the US FDA works to cut time necessary to approve expanded access applications, sponsors are creating delays by mandating patients and institutions sign contracts to gain access.